DrugDashboards

Temozolomide

Temozolomide · TEMOZOLOMIDE 100 mg/1 · Capsule · Oral · Amneal Pharmaceuticals LLC

NDC 65162-0803-51 · 1 BOTTLE in 1 CARTON / 5 CAPSULE in 1 BOTTLE · ANDA · View full market →

The short version

7 companies supply this market — a reasonable cushion if one runs into trouble. The price has fallen 47% in a year, to $4.76 per unit — and generics that get this cheap tend to get abandoned rather than defended. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$4.76per EAinvoice-surveyed acquisition cost · Aug 19, 2026
  • Medicare Part B pays (ASP+6%)$0.4250per billing unit (5 MG)HCPCS J8700 · Jul 1, 2026
  • Part D plans paid (avg)$52.06per dosage unitgross, before rebates — matched by drug name · 2024
  • Federal contracts pay (FSS)$11.32per unitAvKare, LLC · Jun 15, 2023238% of what pharmacies pay — higher than 81% of drugs with this benchmark
  • Medicaid generic ceiling (FUL)$13.13per CAPweighted avg manufacturer price $7.5023 · Aug 1, 2026276% of what pharmacies pay — higher than 90% of drugs with this benchmark

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$50.00$100.00$150.00Jun 2015Sep 2026$4.76
32 price points · per EA · dashed = manufacturer avg (WAMP)Source: CMS NADAC

Estimated fill cost

#30 count
$142.83
#90 count
$428.49

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Medicare Part B (ASP)

Payment limit per 5 MG
$0.425
HCPCS J8700 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$38,822
156 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

23● Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • Class I/II recall on same molecule/form in past 12 months+8
  • price down 47% year over year+15

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for temozolomide (oral solid) in the next 90 days

OAI inspection at a producing facility (24 months) · sole-source market · 1 Class I/II recall(s) in 12 months

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
ANDA203691
TE code
AB
Approval date
May 8, 2015
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Temozolomide (Capsule)

LabelerStrengthFirst seenLast seen
Accord Healthcare Inc.TEMOZOLOMIDE 250 mg/1Jul 15, 2026Sep 2, 2026
Accord Healthcare Inc.TEMOZOLOMIDE 20 mg/1Jul 15, 2026Sep 2, 2026
Accord Healthcare Inc.TEMOZOLOMIDE 180 mg/1Jul 15, 2026Sep 2, 2026
Accord Healthcare Inc.TEMOZOLOMIDE 100 mg/1Jul 15, 2026Sep 2, 2026
Accord Healthcare Inc.TEMOZOLOMIDE 140 mg/1Jul 15, 2026Sep 2, 2026
Accord Healthcare Inc.TEMOZOLOMIDE 5 mg/1Jul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals LLCTEMOZOLOMIDE 140 mg/1Jul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals LLCTEMOZOLOMIDE 250 mg/1Jul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals LLCTEMOZOLOMIDE 100 mg/1Jul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals LLCTEMOZOLOMIDE 20 mg/1Jul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals LLCTEMOZOLOMIDE 5 mg/1Jul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals LLCTEMOZOLOMIDE 180 mg/1Jul 15, 2026Sep 2, 2026
Ascend Laboratories, LLCTEMOZOLOMIDE 180 mg/1Jul 15, 2026Sep 2, 2026
Ascend Laboratories, LLCTEMOZOLOMIDE 140 mg/1Jul 15, 2026Sep 2, 2026
Ascend Laboratories, LLCTEMOZOLOMIDE 100 mg/1Jul 15, 2026Sep 2, 2026
Ascend Laboratories, LLCTEMOZOLOMIDE 250 mg/1Jul 15, 2026Sep 2, 2026
Ascend Laboratories, LLCTEMOZOLOMIDE 20 mg/1Jul 15, 2026Sep 2, 2026
Ascend Laboratories, LLCTEMOZOLOMIDE 5 mg/1Jul 15, 2026Sep 2, 2026
Bryant Ranch PrepackTEMOZOLOMIDE 100 mg/1Jul 15, 2026Sep 2, 2026
Bryant Ranch PrepackTEMOZOLOMIDE 250 mg/1Jul 15, 2026Sep 2, 2026
Bryant Ranch PrepackTEMOZOLOMIDE 20 mg/1Jul 15, 2026Sep 2, 2026
Bryant Ranch PrepackTEMOZOLOMIDE 5 mg/1Jul 15, 2026Sep 2, 2026
Bryant Ranch PrepackTEMOZOLOMIDE 140 mg/1Jul 15, 2026Sep 2, 2026
Bryant Ranch PrepackTEMOZOLOMIDE 180 mg/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.TEMOZOLOMIDE 5 mg/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.TEMOZOLOMIDE 20 mg/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.TEMOZOLOMIDE 250 mg/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.TEMOZOLOMIDE 100 mg/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.TEMOZOLOMIDE 180 mg/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.TEMOZOLOMIDE 140 mg/1Jul 15, 2026Sep 2, 2026
CivicaScript LLCTEMOZOLOMIDE 20 mg/1Jul 15, 2026Sep 2, 2026
CivicaScript LLCTEMOZOLOMIDE 100 mg/1Jul 15, 2026Sep 2, 2026
CivicaScript LLCTEMOZOLOMIDE 5 mg/1Jul 15, 2026Sep 2, 2026
CivicaScript LLCTEMOZOLOMIDE 140 mg/1Jul 15, 2026Sep 2, 2026
CivicaScript LLCTEMOZOLOMIDE 180 mg/1Jul 15, 2026Sep 2, 2026
CivicaScript LLCTEMOZOLOMIDE 250 mg/1Jul 15, 2026Sep 2, 2026
Devatis, Inc.TEMOZOLOMIDE 180 mg/1Jul 15, 2026Sep 2, 2026
Devatis, Inc.TEMOZOLOMIDE 250 mg/1Jul 15, 2026Sep 2, 2026
Devatis, Inc.TEMOZOLOMIDE 140 mg/1Jul 15, 2026Sep 2, 2026
Devatis, Inc.TEMOZOLOMIDE 5 mg/1Jul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Temozolomide — NDC 65162-0803-51," retrieved September 3, 2026, https://drugdashboards.com/drug/65162080351.

Free to cite with attribution — see how the data is put together.